瑞马唑仑在麻醉儿童中静脉输注的药代动力学
瑞马唑仑呈三室模型,清除率高、终末半衰期短,4 h输注后时量相关半衰期为17 min;代谢物CNS7054清除率低、半衰期长。
要点
- 瑞马唑仑在儿童中清除率高、时量相关半衰期短。
- 按体重归一化后药代动力学与成人报道相似。
- 代谢物CNS7054清除率低、终末半衰期长。
核心结论
- 瑞马唑仑在儿童中表现为高清除率和短时量相关半衰期。
- 按体重归一化后,其药代动力学性质与成人报道相似。
研究设计与样本
- 瑞马唑仑以5 mg kg⁻¹ h⁻¹输注5 min,随后以1.5 mg kg⁻¹ h⁻¹输注55 min。
- 采用超高效液相色谱-质谱法测定动脉血中瑞马唑仑及代谢物CNS7054浓度,并进行群体药代动力学建模。
主要发现
- 瑞马唑仑药代动力学最佳描述为三室模型,CNS7054为二室模型,两者经转运室连接。
- 瑞马唑仑清除率为15.9(12.9,18.2)ml kg⁻¹ min⁻¹(中位数,Q25,Q75),中央分布容积为0.11(0.08,0.14)L kg⁻¹,终末半衰期为67(49,85)min。
- 输注4 h后时量相关半衰期为17(12,21)min。
- 代谢物CNS7054清除率为0.89(0.33,1.40)ml kg⁻¹ min⁻¹,中央分布容积为0.011(0.005,0.016)L kg⁻¹,终末半衰期为321(230,770)min。
临床怎么用
- 儿童使用瑞马唑仑时可参考其高清除率和短时量相关半衰期进行给药与苏醒评估。
- 代谢物CNS7054半衰期长,需关注其蓄积与延迟效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The pharmacokinetic properties of the new benzodiazepine remimazolam have been studied only in adults. We investigated the pharmacokinetics of remimazolam after i.v. infusion in anaesthetised paediatric patients. METHODS: Twenty-four children (2-6 yr, ASA physical status 1-2, BMI 15-18 kg m-2) undergoing general anaesthesia with sevoflurane were enrolled. During surgery, remimazolam was administered as an i.v. infusion over 1 h at 5 mg kg-1 h-1 for 5 min, followed by 1.5 mg kg-1 h-1 for 55 min. Plasma concentrations of remimazolam and its metabolite CNS7054 were determined from arterial blood samples using ultra-high performance liquid chromatography-mass spectrometry. Pharmacokinetic modelling was performed by population analysis. RESULTS: Pharmacokinetics were best described by a three-compartment model for remimazolam and a two-compartment model for CNS7054 linked by a transit compartment. Remimazolam showed a high clearance of 15.9 (12.9, 18.2) ml kg-1 min-1 (median, Q25, Q75), a small central volume of distribution of 0.11 (0.08, 0.14) L kg-1 and a short terminal half-life of 67 (49, 85) min. The context-sensitive half-time after an infusion of 4 h was 17 (12, 21) min. The metabolite CNS7054 showed a low clearance of 0.89 (0.33, 1.40) ml kg-1 min-1, a small central volume of distribution of 0.011 (0.005, 0.016) L kg-1, and a long terminal half-life of 321 (230, 770) min. CONCLUSIONS: Remimazolam in children was characterised by a high clearance and short context-sensitive half-time. When normalised to weight, pharmacokinetic properties were similar to those reported for adults. CLINICAL TRIAL REGISTRATION: ChiCTR2200057629.
引用
- Gao YQ, Ihmsen H, Hu ZY, et al. Pharmacokinetics of remimazolam after intravenous infusion in anaesthetised children. Br J Anaesth. 2023. PMID: 37739904. doi:10.1016/j.bja.2023.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。